These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 22713509)

  • 1. Methotrexate in inflammatory bowel disease: a multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience.
    González-Lama Y; Taxonera C; López-Sanromán A; Pérez-Calle JL; Bermejo F; Pajares R; McNicholl AG; Opio V; Mendoza JL; López P; Algaba A; Estelles J; Barbero A; Mendoza J; Maté J; Gisbert JP;
    Eur J Gastroenterol Hepatol; 2012 Sep; 24(9):1086-91. PubMed ID: 22713509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice.
    Domènech E; Mañosa M; Navarro M; Masnou H; Garcia-Planella E; Zabana Y; Cabré E; Gassull MA
    J Clin Gastroenterol; 2008 Apr; 42(4):395-9. PubMed ID: 18277899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
    Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
    Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of methotrexate for treatment of inflammatory bowel disease in clinical practice.
    Saibeni S; Bollani S; Losco A; Michielan A; Sostegni R; Devani M; Lupinacci G; Pirola L; Cucino C; Meucci G; Basilisco G; D'Incà R; Bruno S
    Dig Liver Dis; 2012 Feb; 44(2):123-7. PubMed ID: 22051323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
    Pearce CB; Lawrance IC
    J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
    Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
    Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
    Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
    Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V
    Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory bowel disease: current therapeutic options.
    Domènech E
    Digestion; 2006; 73 Suppl 1():67-76. PubMed ID: 16498254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited?
    Charpignon C; Beau P
    Gastroenterol Clin Biol; 2008 Feb; 32(2):153-7. PubMed ID: 18343615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and tolerability of methotrexate for treating patients with Crohn's disease.
    Chande N; Abdelgadir I; Gregor J
    J Clin Gastroenterol; 2011 Aug; 45(7):599-601. PubMed ID: 21224737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral methotrexate in ulcerative colitis.
    Cummings JR; Herrlinger KR; Travis SP; Gorard DA; McIntyre AS; Jewell DP
    Aliment Pharmacol Ther; 2005 Feb; 21(4):385-9. PubMed ID: 15709988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
    Markowitz J; Grancher K; Mandel F; Daum F
    Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Optimizing effect of infliximab upon inflammatory bowel disease].
    Li SR; Sheng JQ; Li SJ; Zhao XJ
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(36):2568-70. PubMed ID: 20137621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration.
    Nathan DM; Iser JH; Gibson PR
    J Gastroenterol Hepatol; 2008 Jun; 23(6):954-8. PubMed ID: 17559377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
    Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.
    Baumgart DC; Pintoffl JP; Sturm A; Wiedenmann B; Dignass AU
    Am J Gastroenterol; 2006 May; 101(5):1048-56. PubMed ID: 16573777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.